These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 23834917)
1. Differences in immunological responses of polyclonal botulinum A1 and A2 antitoxin against A1 and A2 toxin. Torii Y; Shinmura M; Kohda T; Kozaki S; Takahashi M; Ginnaga A Toxicon; 2013 Oct; 73():9-16. PubMed ID: 23834917 [TBL] [Abstract][Full Text] [Related]
2. Comparison of the immunogenicity of botulinum toxin type A and the efficacy of A1 and A2 neurotoxins in animals with A1 toxin antibodies. Torii Y; Goto Y; Nakahira S; Kozaki S; Ginnaga A Toxicon; 2014 Jan; 77():114-20. PubMed ID: 24269688 [TBL] [Abstract][Full Text] [Related]
3. Development of an Equine Antitoxin by Immunizing the Halla Horse with the Receptor-Binding Domain of Botulinum Neurotoxin Type A1. Kim NY; Park KE; Lee YJ; Kim YM; Hong SH; Son WR; Hong S; Lee S; Ahn HB; Yang J; Seo JP; Lim YK; Yu CH; Hur GH; Jeong ST; Lee HS; Song K; Kang TJ; Shin YK; Choi JS; Choi JY J Microbiol Biotechnol; 2019 Jul; 29(7):1165-1176. PubMed ID: 31280529 [TBL] [Abstract][Full Text] [Related]
4. Anomalous enhancement of botulinum toxin type A neurotoxicity in the presence of antitoxin. Sheridan RE; Deshpande SS; Amersdorfer P; Marks JD; Smith T Toxicon; 2001 May; 39(5):651-7. PubMed ID: 11072043 [TBL] [Abstract][Full Text] [Related]
5. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Smith TJ; Lou J; Geren IN; Forsyth CM; Tsai R; Laporte SL; Tepp WH; Bradshaw M; Johnson EA; Smith LA; Marks JD Infect Immun; 2005 Sep; 73(9):5450-7. PubMed ID: 16113261 [TBL] [Abstract][Full Text] [Related]
6. Study on the immunological heterogeneity of Clostridium botulinum B type toxin. Rymkiewicz D; Sawicki J; Brühl A Arch Immunol Ther Exp (Warsz); 1979; 27(5):709-14. PubMed ID: 398207 [TBL] [Abstract][Full Text] [Related]
7. Characterization of the monoclonal antibody response to botulinum neurotoxin type A in the complexed and uncomplexed forms. Zhao H; Nakamura K; Kohda T; Mukamoto M; Kozaki S Jpn J Infect Dis; 2012; 65(2):138-45. PubMed ID: 22446121 [TBL] [Abstract][Full Text] [Related]
8. [Identification of strain B 657 of Clostridium botulinum]. Giménez DF; Giménez JA Rev Argent Microbiol; 1983; 15(1):51-5. PubMed ID: 6400761 [TBL] [Abstract][Full Text] [Related]
9. An in vitro cell-based potency assay for pharmaceutical type A botulinum antitoxins. Torgeman A; Diamant E; Levin L; David AB; Epstein E; Girshengorn M; Mazor O; Rosenfeld R; Zichel R Vaccine; 2017 Dec; 35(52):7213-7216. PubMed ID: 29174678 [TBL] [Abstract][Full Text] [Related]
10. Comparison of effects of botulinum toxin subtype A1 and A2 using twitch tension assay and rat grip strength test. Torii Y; Kiyota N; Sugimoto N; Mori Y; Goto Y; Harakawa T; Nakahira S; Kaji R; Kozaki S; Ginnaga A Toxicon; 2011 Jan; 57(1):93-9. PubMed ID: 21029745 [TBL] [Abstract][Full Text] [Related]
11. Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats. Torii Y; Goto Y; Nakahira S; Kozaki S; Kaji R; Ginnaga A Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):524-8. PubMed ID: 25395371 [TBL] [Abstract][Full Text] [Related]
12. Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats. Torii Y; Akaike N; Harakawa T; Kato K; Sugimoto N; Goto Y; Nakahira S; Kohda T; Kozaki S; Kaji R; Ginnaga A J Pharmacol Sci; 2011; 117(4):275-85. PubMed ID: 22123262 [TBL] [Abstract][Full Text] [Related]
13. Standardization of the Japanese National Standard, Equine Botulinum Antitoxin Type A, and Factors Affecting Standardization. Yutani M; Senoh M; Yano H; Kenri T; Iwaki M Jpn J Infect Dis; 2024 Jan; 77(1):16-20. PubMed ID: 37648491 [TBL] [Abstract][Full Text] [Related]
14. A cell-based alternative to the mouse potency assay for pharmaceutical type E botulinum antitoxins. Diamant E; Torgeman A; Epstein E; Mechaly A; David AB; Levin L; Schwartz A; Dor E; Girshengorn M; Barnea A; Mazor O; Zichel R ALTEX; 2022; 39(1):113-122. PubMed ID: 34798660 [TBL] [Abstract][Full Text] [Related]
15. Use of in vitro Vero cell assay and ELISA in the United States potency test of vaccines containing adsorbed diphtheria and tetanus toxoids. Gupta RK; Siber GR Dev Biol Stand; 1996; 86():207-15. PubMed ID: 8785950 [TBL] [Abstract][Full Text] [Related]
16. Quantification of potency of neutralizing antibodies to botulinum toxin using compound muscle action potential (CMAP). Torii Y; Takahashi M; Ishida S; Goto Y; Nakahira S; Harakawa T; Kaji R; Kozaki S; Ginnaga A Toxicon; 2010; 55(2-3):662-5. PubMed ID: 19781565 [TBL] [Abstract][Full Text] [Related]
17. Purification and characterization of a novel subtype a3 botulinum neurotoxin. Tepp WH; Lin G; Johnson EA Appl Environ Microbiol; 2012 May; 78(9):3108-13. PubMed ID: 22367089 [TBL] [Abstract][Full Text] [Related]
18. New equine antitoxins to botulinum neurotoxins serotypes A and B. Li D; Mattoo P; Keller JE Biologicals; 2012 Jul; 40(4):240-6. PubMed ID: 22560800 [TBL] [Abstract][Full Text] [Related]
19. An improved method for development of toxoid vaccines and antitoxins. Jones RG; Liu Y; Rigsby P; Sesardic D J Immunol Methods; 2008 Aug; 337(1):42-8. PubMed ID: 18571196 [TBL] [Abstract][Full Text] [Related]
20. Mouse compound muscle action potential assay: an alternative method to conduct the LD₅₀ botulinum toxin type A potency test. Kim SH; Kim SB; Yang GH; Rhee CH Toxicon; 2012 Sep; 60(3):341-7. PubMed ID: 22613167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]